Reuters logo
BRIEF-Janssen Sciences Ireland UC says positive results from first Phase III studies of investigational two-drug HIV treatment regimen
December 19, 2016 / 11:24 PM / 9 months ago

BRIEF-Janssen Sciences Ireland UC says positive results from first Phase III studies of investigational two-drug HIV treatment regimen

Dec 19 (Reuters) - Janssen Sciences Ireland UC -

* Press release - Positive results from first Phase III studies of investigational two-drug HIV treatment regimen

* Janssen Sciences Ireland UC - Rilpivirine (Janssen) and Dolutegravir (ViiV Healthcare) met primary endpoint of non inferiority at week 48

* Janssen Sciences Ireland UC - Anticipated that regulatory submissions for Rilpivirine and Dolutegravir as a single tablet will be made in 2017 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below